Focus on Transplantation: Treatment Post-transplant for HBV and HCV
|
|
- Roderick Nash
- 8 years ago
- Views:
Transcription
1 Focus on Transplantation: Treatment Post-transplant for HBV and HCV The Viral Hepatitis Congress, Frankfurt, 09. September 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische Klinik I Frankfurt am Main, Germany
2 Disclosures Speakers bureau, consulting and/or research grants by Abbott, Boehringer, BMS, Gilead, Janssen, MSD/Merck, Rottapharm, Roche, Vertex
3 Hepatitis B Post-Transplant
4 Natural course of hepatitis B after liver transplantation (OLT) Universal reinfection of the graft in pts. with chr. hepatitis B associated with ~50% graft / patient survival at 5 years FU n=6033 Survival after OLT between recipients with HBV and those with other diagnoses before introduction of reinfection prophylaxis (UNOS) n=675 Kim et al., Liver Transpl HBV-related liver disease as a contraindication for OLT
5 Introduction of Hepatitis B Immune Globulin (HBIG) Binding to and neutralizing circulating virions by long-term, repeated administration of HBIG p<0.001 Survival after OLT comparing no prophylaxis, short-term ( 2 months) and long-term ( 6 months) HBIG prophylaxis in 359 patients from Europe Samuel et al., NEJM 1993
6 Introduction of a direct antiviral agent: nucleoside analogue lamivudine Antiviral activity against hepatitis B Safe in cirrhotics and transplant pts. and prevention of reinfection after OLT (9/10 pts. with >20 wks. survival after OLT) n=32 Dienstag et al., NEJM 1995 Grellier et al., Lancet 1996
7 Establishment of a new standard for hepatitis B and liver transplantation Combination therapy of long-term HBIG plus Lamivudine n=19007 n=1723 Kim et al., Liver Transpl Mile stone for management of hepatitis B after OLT with <5% recurrence at 5y FU but: - HBIG is expensive - HBIG has to be administered i.v. every 4 weeks - Lamivudine has a low barrier to resistance with frequent viral break-through HBV-related liver disease as a preferred indication for OLT
8 Low-dose HBIG IU versus 2000 IU per month HBIG + Lamivudine low dose HBIG + Lamivudine n=147, HBIG IU i.m. per month plus Lam +/- Adefovir median follow-up 1860 days (~5 years) 1% and 4% risk of HBV recurrence at 1 and 5 years after OLT n=5 patients with recurrence (HBsAg and HBV DNA pos.) Alternatively 500 IU s.c. every (other) week Recurrence in all patients was associated with Lamivudine resistance Gane et al., Gastroenterology 2007
9 Nucleos(t)ide Mono- /Combo-Therapy Ensuring high barrier to resistance Nucleos(t)ide Analogue Mono / Combo n=80, monotherapy with Entecavir, no HBIG median follow-up 26 months n=10 patients with recurrence (HBsAg pos.) 18 patients with detectable HBsAg at their last visit (23%) 17/18 patients had undetectable HBV- DNA Importance of adherence Fung et al., Gastroenterology 2011
10 Switch to Nucleos(t)ide Mono- / Combo- Therapy HBIG + Nuc. Nucleos(t)ide Analogue Combo n=61, after 12 months HBIG+Nuc and stable conditions switch to Nuc combo (mainly LAM + Entecavir), mean follow-up 15 months 2 cases with reappearance (3.3%) Saab et al., Am J Transplant 2011
11 Active vaccination followed by discontinuation of prophylaxis HBIG + Lamivudine Active Vaccination n=17 in each study, all HBeAg- + HBV-DNA neg. before & after OLT; after 18 months HBIG +/- Lam 1-3 HBV vaccine cycles (à 3x40µg) 14/17 with antihbs >10 IU/l (82%) 3/17 with antihbs >10 IU/l (18%) Selection of pts., high doses, boosting required and LT follow-up? Sanchez-Fueyo et al., Hepatology 2000 Angelico et al., Hepatology 2002; Di Paolo et al., Dig Dis Sci 2006
12 Discontinuation of prophylaxis Measurement of cccdna / HBV DNA in the liver HBIG + Lamivudine Stop n=30, HBeAg- + HBV-DNA neg. before & after OLT; m. post OLT 25/30 without HBV recurrence HBV DNA and cccdna undetectable in the liver Lenci et al., J Hepatol 2011
13 Hepatitis C Post-Transplant
14 Natural course of hepatitis C after liver transplantation (OLT) HCV Re-Infection after OLT is associated with reduced survival 76,6% 69,9% Gane EJ et al., NEJM 1996, Forman et al., Gastroenterology 2002
15 Natural course of hepatitis C after liver transplantation (OLT) fibrosing cholestatic hepatitis C 2-6% OLT > 99% HCV RNA % acute hepatitis 50-98% chron. hepatitis 8-44% cirrhosis 42-63% decomp. 1-3 years 0 72h 1-4 mo >4-6 mo 1-15 years accord. to Berenguer M. Clin Liver Dis 2007
16 Acute Hepatitis C re-infection Treatment of "acute hepatitis C" HCV-RNA (copies/ml) Days after liver transplantation Fukumoto et al. Hepatology 1996 Berg et al. Transplantation 1998
17 Treatment of acute hepatitis C after OLT pre-emptive therapy Studies pre-emptive treatment High rates of complications High immuno suppression required Limited tolerability (discontinuation rates up to 60%) Frequent dose reductions (>70%) Limited SVR rates (8-39%) No general pre-emptive treatment Option for individual patients with severe reinfection and favorable virological profile Chalasani et al., Hepatology 2005, Sugawa et al., Transplantation 2004, Kuo et al., Liver Transpl 2008, Sheiner et al., Hepatology 1998, Singh et al., Transplantation 1998, Castells et al., J Hepatol 2005
18 Treatment of recurrent hepatitis C 4-6 months after OLT Therapy if histologically proven recurrent hepatitis C Limited tolerability: ~ 1/3 discontinuation (4-55%) ~ 60% dose reductions Sustained virologic response: ~ 30% Genotype 1 ~ 50% Genotype 2/3 Negative predictors: - cirrhosis of liver graft - virologic null-response - donor age No correlation: - CSA versus Tacrolimus - PEG2a vs PEG2b - Virolog. response previous therapy Morard und Negro, J Hepatol 2005, Berenguer et al., Liver Transpl 2009 Carrion et al., Gastroenterology 2007, Peveling et al., Med Microbiol Immunol 2009
19 Treatment of hepatitis C after OLT Improved survival (PEG)-IFN / Riba treatment after OLT, n=89, SVR 37% 93% 74% 62% p=0,04 69% p=0,032 7 years Treatment vs. Control SVR vs. Non-SVR Potentially also effective to prevent recurrence of HCC (n=46, retrospective) Berenguer et al., Am J Transplant 2008, Kohli et al., Transpl Int 2012
20 Treatment of hepatitis C after OLT Importance of IL28B polymorphism Importance of graft and donor IL28B genotype (rs ) with virologic response to IFN-based therapy after OLT (n=46) Association of IL28B T-allele with vir. resp. & fibrosis progression after OLT, (n=167) Lange et al., J Hepatol 2011; Eurich et al., Transplantation 2012
21 Future aims: Direct antiviral agents for treatment of hepatitis C after OLT HCV NS3 protease inhibitors (Telaprevir / Boceprevir) in combination with PEG-Interferon and Ribavirin (Triple-Therapy) HCV RNA undetectable at week 16 [%] PR-TVR HCV RNA undetectable at week 8 [%] PR-TVR 56 PR-BOC Pts. with previous NR (n=7) or severe recurrent hepatitis C (n=28) Reduction of immunosuppr. doses, anemia most common AE Kwo et al., EASL 2012; Coilly et al., EASL 2012
22 Future aims: Prevention of re-infection Direct inhibition of HCV replication by i.v. silibinin 57 years, male HCV-3a, NR cirrhosis, HCC Child C, MELD 23 20mg/kg BW 61 years, male HCV-1a/4, NR cirrhosis, Child C, MELD years, female HCV-2a, Relapse cirrhosis, HCC, Child C, MELD 20 Ferenci et al., Gastroenterology 2008; Neumann et al., J Hepatol 2010; Beinhardt et al., J Hepatol 2011; Aghemo et al., Hepat Mon 2012
23 Summary Hepatitis B after liver transplantation - Standard prophylaxis: HBIG plus Nucleos(t)ide - Reinfection is mainly associated with viral load pre OLT - Low dose HBIG in combination with Nuc - Switch or Nuc only leads to higher HBs-ag reappearance but suppressed HBV DNA (compliance!) - Discontinuation of prophylaxis needs further predictors Hepatitis C after liver transplantation - No general pre-emptive PEG-IFN/Riba therapy - Treatment of transplant hepatitis with PEG-IFN/Riba with poor tolerability and limited SVR rates - Triple-Therapy with Protease-Inh. Telaprevir / Boceprevir - Future aim: prevention of re-infection
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV
Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationManagement of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok
Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US
More informationTreatment Options for Hepatitis C in the Post Transplant Patient
Treatment Options for Hepatitis C in the Post Transplant Patient Caroline Rochon, MD, FACS,FRCSC Transplant and Hepatobiliary Surgery Hartford Hospital Assistant Professor of Surgery, University of Connecticut
More informationRecurrent HCV Following Liver Transplantation
Recurrent HCV Following Liver Transplantation Russell H. Wiesner, MD Professor of Medicine Mayo Clinic College of Medicine Rochester, MN, USA ILTS Western/Eastern Perspective Hong Kong, CHINA April 5-6,
More informationOptimising therapy in chronic hepatitis B: Switch or add treatment
Optimising therapy in chronic hepatitis B: Switch or add treatment Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of Songkla University,Thailand NA + NA Percent with resistance
More informationHEPATITIS COINFECTIONS
HEPATITIS COINFECTIONS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures (Activity w/i 12 months)
More informationPost AASLD Update in HCV Torino, 10 Gennaio 2013. Fattori che possono influenzare il trattamento: RVR e Lead in
Post AASLD Update in HCV Torino, 10 Gennaio 2013 Fattori che possono influenzare il trattamento: RVR e Lead in Alessia Ciancio Università di Torino Città della Salute e delle Scienze Will predictors usefull
More informationLong-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B
Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B Patrick Marcellin Viral Hepatitis Research Center Hôpital Beaujon, University of Paris France OBJECTIVES OF THERAPY IN CHRONIC
More informationMedical publications on HBV and HCV Coinfection
Recent advances of HBV and HCV co-infection 台 中 榮 總 內 科 部 胃 腸 肝 膽 科 呂 宜 達 醫 師 2013.03.28 Outline Epidemiology of HBV and HCV coinfection Clinical significance of HBV and HCV coinfection Interplay between
More informationEfficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients
Second Silibinin Workshop, Cologne, 23 rd May 2014 Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C coinfected patients Dominique L Braun, MD Division of
More informationVirology. Behandlung der Hepatitis B. HBV Genome. HBV life cycle. HBV Genotypes. Natural History. 8 genotypes: A, B, C, D, E, F, G, H
Virology Behandlung der Hepatitis B Markus Heim Universitätsspital Basel 1 2 HBV Genome HBV life cycle 3 4 HBV Genotypes Natural History 8 genotypes: A, B, C, D, E, F, G, H genotypes A and D are prevalent
More informationHBV Treatment Guidelines. By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine
HBV Treatment Guidelines By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine A 29 Y old lady diagnosed as chronic HBV 3 years ago during her pregnancy, no treatment
More informationClinical Application of HBs quantification
Clinical Application of HBs quantification Hepatology on the Nile 2 Advances in Liver Disease 2014, "World Expert Review» Wednesday, September 24, 2014 Pr Tarik Asselah MD, PhD; Service d Hépatologie &
More informationAfter the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
More informationLA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova
LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova HBV ed HCV Due virus Diversi ma con molte Cose in Comune
More informationHepatitis C and Liver Transplantation. Dinesh Ranjan, M.D. Professor of Surgery Director of Liver Transplantation University of Kentucky
Hepatitis C and Liver Transplantation Dinesh Ranjan, M.D. Professor of Surgery Director of Liver Transplantation University of Kentucky History Known as Non-A A Non-B B Hepatitis in 1974 HCV identified
More informationManagement of Chronic Hepatitis B: 2012 Update
Management of Chronic Hepatitis B: 2012 Update Brian J McMahon MD, Liver Disease and Hepatitis Program Alaska Native Medical Center and Arctic Investigations Program, CDC Conflicts of Interest The Liver
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationPeg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?
Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics? Prof. I. Bakulin Gastroenterology Department Key Questions Background Worldwide prevalence
More informationHepatitis C Glossary of Terms
Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune
More informationManagement of Chronic HCV Cirrhosis: Pre and Post-Liver Transplantation
Management of Chronic HCV Cirrhosis: Pre and Post-Liver Transplantation K.Rajender Reddy M.D., Professor of Medicine and Surgery Director of Hepatology Director, Viral Hepatitis Center Transplantation
More informationTreatment of Hepatitis B
Treatment of Hepatitis B Paul Y Kwo, MD Professor of Medicine Gastroenterology/Hepatology Division Medical Director, Liver Transplantation Indiana University Health Indiana University School of Medicine
More information17/01/14. What are special patient groups? Management of hepatitis C in special patient groups. Management of hepatitis C in
Management of hepatitis C in special patient groups Minisymposium Challenges in viral hepatitis 14 Lausanne 16.1.14 B. Müllhaupt Gastroenterology and Hepatology Swiss HPB- and Transplant-Center University
More informationLamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine
Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重
More informationHCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain
HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening
More informationCurrent Opinion in Hepatitis C Treatment
White Nights of Hepatology 2011 Current Opinion in Hepatitis C Treatment George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal Medicine, Athens University
More informationHIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
More informationVictrelis: hints for success. Katarnya Gilbert Hepatology MSL MSD
Victrelis: hints for success Katarnya Gilbert Hepatology MSL MSD 1 Some Facts: BOC has no clinically significant activity against other HCV genotypes. Resistance with protease inhibitor monotherapy can
More informationDr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor. Hepatology-2014
Dr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor Hepatology-2014 Other virus hepatitis Epstein-Barr vírus Cytomegalo vírus Herpes simplex vírus Coxsackie vírus Hepatitis B vírus Hepadnavírus,
More informationPURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.
COVENTRY Health Care Guidelines for Hepatitis B Therapy SUBJECT: Chronic Hepatitis B Therapy: a. Interferons - Intron A (interferon alfa-2b) and Pegasys (peginterferon alfa-2a) b. Nucleoside analogues
More informationHIV/Hepatitis C co-infection. Update on treatment Eoin Feeney
HIV/Hepatitis C co-infection Update on treatment Eoin Feeney HIV/Hepatitis C coinfection Where we are now Current treatment regimens and outcomes What s coming soon Direct acting antivirals (DAAs) What
More informationInnovazione farmacologica e farmacologia clinica
Innovazione farmacologica e farmacologia clinica Francesco Scaglione, MD, PhD Department of Medical Biotechnology and Translational Medicine School of medicine Postgradute School of clinical pharmacology
More informationHepatitis B reactivation. Geoffrey Dusheiko UCL Institute for Liver and Digestive Health Royal Free Hospital London, UK
Hepatitis B reactivation Geoffrey Dusheiko UCL Institute for Liver and Digestive Health Royal Free Hospital London, UK HBV reactivation Defined as abrupt rise in HBV replication (> 1 log) Followed by lab
More informationHepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas
Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas Hepatitis C Virus Shimizu et al., 1996 Positive single strand RNA virus Flaviviridae family, Hepacivirus genus 9.6 kbp genome ~3000
More informationMonitoring of Treatment of viral hepatitis C
Monitoring of Treatment of viral hepatitis C J.Boubaker Department of Gastroenterology La Rabta hospital Tunis-Tunisia Monitoring of Hepatitis C Treatment Aims of Monitoring : Evaluate Efficacy. Detect
More informationSafety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B
Safety of Nucleos(t)ide Analogues during Long-Term Treatment of Chronic Hepatitis B Anna S. F. Lok, MD Alice Lohrman Andrews Research Professor in Hepatology Director of Clinical Hepatology University
More informationNew treatment options for HCV: implications for the Optimal Use of HCV Assays
New treatment options for HCV: implications for the Optimal Use of HCV Assays Hans Orlent Dept. of Gastroenterology & Hepatology AZ Sint Jan Brugge-Oostende, Brugge This program is supported by educational
More informationHepatitis C Class Review
Hepatitis C Class Review Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January
More informationEASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version)
Journal of Hepatology 38 (2003) 533 540 Special article EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B 13 14 September, 2002 Geneva, Switzerland Consensus statement (Short version) The EASL Jury*
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B
Journal of Hepatology 50 (2009) 227 242 www.elsevier.com/locate/jhep EASL Clinical Practice Guidelines: Management of chronic hepatitis B European Association for the Study of the Liver * Keywords: Hepatitis
More informationCoinfezione HIV-HCV. Raffaele Bruno, MD. Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Coinfezione HIV-HCV Raffaele Bruno, MD This program is supported by educational grants from Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
More informationHCV Pipeline: The Next 18 Months Michael W. Fried, MD
HCV Pipeline: The Next 18 Months Michael W. Fried, MD Professor of Medicine Director, UNC Liver Center University of North Carolina at Chapel Hill Michael W. Fried, MD Commercial Disclosures Grants/Research
More informationDoes pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?
180 Campos-Varela I, et al., 2011; 10 (2): 180-187 ORIGINAL ARTICLE April-June, Vol. 10 No.2, 2011: 180-187 Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant
More informationThe availability of newer antiviral agents, as
TREATMENT OF HEPATITIS B VIRUS INFECTION * Norman L. Sussman, MD ABSTRACT In treating chronic hepatitis B virus (HBV) infection, the primary goal of therapy is to achieve sustained suppression of HBV replication,
More informationUPDATE ON NEW HEPATITIS C MEDICINES
UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationNew IDSA/AASLD Guidelines for Hepatitis C
NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation
More informationThe question and answer session is not available after the live webinar.
1 Read verbatim. 2 The Infectious Diseases Society of America (IDSA) Hepatitis C Knowledge Network offers monthly, 1 hour webinars to educate IDSA members on current recommended practices and treatments
More informationMEDICAL POLICY STATEMENT
MEDICAL POLICY STATEMENT Original Effective Date Next Annual Review Date Last Review / Revision Date 5/21/2014 3/24/2016 3/24/2015 Policy Name Policy Number Hepatitis C Oral SRx-0003 Medical Policy Statements
More informationRobert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012
Treatment of Hepatitis C:Present and Future Robert G. Knodell, M.D. Scientific Meeting Maryland Chapter, American College of Physicians Fb February 3, 2012 Presentation Objectives Appreciate the Public
More informationPrior Authorization Policy
Prior Authorization Policy http://www.paramounthealthcare.com/providers Ribavirin Rebetol (ribavirin capsule or oral solution) Copegus (ribavirin tablet), Moderiba (ribavirin tablet), Ribasphere (ribavirin
More informationHIV/HCV Co-infection. HIV/HCV Co-infection. Epidemiology. Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London. Extrahepatic manifestations
HIV/HCV Co-infection Dr Ranjababu Kulasegaram Guy s & St Thomas Hospital London HIV/HCV Co-infection Epidemiology Impact of HIV on HCV Epidemiology Impact of HCV on HIV Management issues Future Extrahepatic
More informationCurrent Antiviral Treatment of HCV cirrhosis
Current Antiviral Treatment of HCV cirrhosis Hugo R. Rosen, M.D. Waterman Endowed Chair in Liver Research Division Head, Gastroenterology & Hepatology Professor of Medicine and Immunology University of
More informationProlonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: The HIDIT-2 study.
Prolonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: The HIDIT-2 study. Heiner Wedemeyer*, Cihan Yurdaydın*, Stefanie Ernst, Florin
More informationPutting progress into practice for HCV care in Egypt
Putting progress into practice for HCV care in Egypt Chairs: Maria Buti, Ashraf Abou-Gabal, Sami Abdel Fattah, Ali Farag, Faisal Sanai This session has been funded by Gilead Sciences Europe The content
More informationDisclosure of Conflicts of Interest Learner Assurance Statement:
Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation
More informationHCV Case Study. Optimizing Outcomes with Current Therapies
HCV Case Study Optimizing Outcomes with Current Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationCase Finding for Hepatitis B and Hepatitis C
Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center
More informationBoehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver
Boehringer Ingelheim- sponsored Satellite Symposium HCV Beyond the Liver HCV AS A METABOLIC MODIFIER: STEATOSIS AND INSULIN RESISTANCE Francesco Negro University Hospital of Geneva Switzerland Clinical
More informationboceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationUpdate on hepatitis C: treatment and care and future directions
Update on hepatitis C: treatment and care and future directions Professor Greg Dore Viral Hepatitis Clinical Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New
More informationMolecular Diagnosis of Hepatitis B and Hepatitis D infections
Molecular Diagnosis of Hepatitis B and Hepatitis D infections Acute infection Detection of HBsAg in serum is a fundamental diagnostic marker of HBV infection HBsAg shows a strong correlation with HBV replication
More informationTreatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011
CLINICAL GUIDELINES DANISH MEDICAL JOURNAL Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011 Peer Brehm Christensen, Mette Rye Clausen, Henrik
More informationManaging Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study
Managing Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study Case Prepared by Sinēad Sheils CNC Royal Prince Alfred Hospital, Sydney Friday 17 th May 2013 Nigel 63 yrs old caucasian male HCV
More informationEmerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C
Emerging Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Debra Birnkrant, MD Director, DAVP DILI Conference March 20, 2013 1 HCV in the United States 3 to 4 million people have chronic HCV
More informationChronic hepatitis B (CHB) remains an important public SPECIAL REPORT
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1315 1341 SPECIAL REPORT A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update EMMET B. KEEFFE,*
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C, genotype and sub-genotype specified to determine the length of therapy; Liver biopsy or other accepted test demonstrating
More informationHepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015
Hepatitis C: Eradication of a Disease? Gordon Dow, MD Oct 16 th, 2015 Disclosures: In the past two years I have participated in research 1 or received consultation/speaking fees 2 from: Astellas 2 Abbvie
More informationHBV screening and management in HIV-infected children and adolescents
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
More informationVirological Monitoring of Hepatitis C Therapy
Virological Monitoring of Hepatitis C Therapy Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University
More informationA 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation.
A 55 year old man with cirrhosis due to chronic hepatitis C (CHC) genotype 3a is referred for liver transplantation. Three years ago he was treated with 24 weeks of peginterferon alfa-2a (180 µg/wk, PEGIFN)
More informationOptimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?
Liver International ISSN 1478-3223 REVIEW ARTICLE Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy? Jorg Petersen 1 and Maura Dandri 2 1 IFI Institute at the Asklepios Klinik
More informationViral Hepatitis Prevention Board Meeting November 2013. The Netherlands: Hepatitis C treatment guidelines
Viral Hepatitis Prevention Board Meeting November 2013 The Netherlands: Hepatitis C treatment guidelines Floor Berden MD, PhD student Radboud university medical center Nijmegen, the Netherlands Conflicts
More informationboceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment experienced patients SMC No. (722/11) Merck, Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationHepatitis Update 2013. Brendan M. McGuire, MD UAB Liver Center
Hepatitis Update 2013 Brendan M. McGuire, MD UAB Liver Center Introduction Hepatitis - Inflammation of the liver Five types A B C D E Characteristics of Hepatitis Viruses Virus Genome Family Major mode
More informationUpdate on Pharmacotherapy of Chronic Hepatitis B and C
Update on Pharmacotherapy of Chronic Hepatitis B and C Rebecca L. Corey, Pharm.D., BCPS Reviewed by Paulina Deming, B.S., Pharm.D., PhC; Lisa C. Hutchison, Pharm.D., MPH, FCCP, BCPS; and Hannah R. Howell,
More informationHepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?
Hepatitis C David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham Substance Misuse Treatment in the West Midlands. How can we reduce harm? Birmingham October 19 th 2007 infection HCV Natural History
More informationHBV DNA < monitoring interferon Rx
Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute
More informationAASLD PRACTICE GUIDELINES Chronic Hepatitis B
AASLD PRACTICE GUIDELINES Chronic Hepatitis B Anna S. F. Lok 1 and Brian J. McMahon 2 This guideline has been approved by the American Association for the Study of Liver Diseases and represents the position
More informationPRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT
PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT HARVONI (90mg ledipasvir/400mg sofosbuvir): tablet (PREFERRED AGENT) SOVALDI (sofosbuvir ): 400mg tablets (PREFERRED AGENT ) OLYSIO (simeprivir) PEG-INTRON
More informationDebate: To Treat Now or Not to Treat Now. Age, Disease Stage, Resistance, and Comorbidities
Debate: To Treat Now or Not to Treat Now Age, Disease Stage, Resistance, and Comorbidities Moderator: Raymond T. Chung, MD Associate Professor of Medicine, Harvard Medical School Director of Hepatology
More information1.1.2 Amend the that the Special Authority relating to tenofovir for use in pregnancy for postpartum care;
Anti-Infective Subcommittee of PTAC Meeting held 1 March 2012 (minutes for web publishing) Anti-Infective Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationPREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto
PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationNewton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP
Newton Kendig, MD RADM, Assistant Surgeon General, USPHS Assistant Director Health Services Division, FBOP I do not have any relevant financial relationships with any commercial interests. At the end of
More informationAASLD PRACTICE GUIDELINES Chronic Hepatitis B: Update 2009
AASLD PRACTICE GUIDELINES Chronic Hepatitis B: Update 2009 Anna S. F. Lok 1 and Brian J. McMahon 2 This guideline has been approved by the American Association for the Study of Liver Diseases and represents
More informationNew Research On Direct-acting Antivirals For The Treatment Of Hepatitis C
New Research On Direct-acting Antivirals For The Treatment Of Hepatitis C Highlights From EASL 214, London, U.K. This report contains highlights from a selection of abstracts and posters presented during
More informationThe Natural History of Hepatitis C Cirrhosis After Liver Transplantation
LIVER TRANSPLANTATION 15:1063-1071, 2009 ORIGINAL ARTICLE The Natural History of Hepatitis C Cirrhosis After Liver Transplantation Roberto J. Firpi,* Virginia Clark,* Consuelo Soldevila-Pico, Giuseppe
More informationTreatment of Hepatitis C in Patients with Renal Insufficiency
HEPATITIS WEB STUDY HEPATITIS C ONLINE Treatment of Hepatitis C in Patients with Renal Insufficiency Robert G. Gish MD Professor Consultant, Stanford University Medical Center Senior Medical Director,
More informationHepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS
Hepatitis B and C Co-infection Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS Objectives Review natural history of hepatitis coinfection Brief overview of treatment indications for
More informationHepatitis C Vaccines: Are we making progress?
Hepatitis C Vaccines: Are we making progress? Second International Hepatitis Cure and Eradication Meeting. Vancouver November, 2015 Objectives: Review the need for a preventive vaccine in 2015. Identify
More informationViral Hepatitis Case Report
Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date
More informationCase Study in the Management of Patients with Hepatocellular Carcinoma
Management of Patients with Viral Hepatitis, Paris, 2004 Case Study in the Management of Patients with Hepatocellular Carcinoma Eugene R. Schiff This 50-year-old married man with three children has a history
More informationManagement of non response or relapse following HCV therapy. Greg Dore Darrell Crawford
Management of non response or relapse following HCV therapy Greg Dore Darrell Crawford Learning objectives To understand importance of characterisation of prior HCV therapy response To explore options
More informationDosaggi Sierologici e Molecolari nelle Epatiti B e C METODI MOLECOLARI. Ombretta Turriziani Dipartimento di Medicina Molecolare
Dosaggi Sierologici e Molecolari nelle Epatiti B e C METODI MOLECOLARI Ombretta Turriziani Dipartimento di Medicina Molecolare Dosaggi Sierologici e Molecolari nelle Epatiti B e C Molecular Methods Key
More informationLiver Transplantation in Asian Patients With Chronic Hepatitis B Using Lamivudine Prophylaxis
ANNALS OF SURGERY Vol. 233, No. 2, 276 281 2001 Lippincott Williams & Wilkins, Inc. Liver Transplantation in Asian Patients With Chronic Hepatitis B Using Lamivudine Prophylaxis Chung-Mau Lo, MS, FRCS
More informationLIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
More informationFuture Challenges in Hepatitis B Treatment. Maria Buti Hospital Universitario Valle Hebron Barcelona
Future Challenges in Hepatitis B Treatment Maria Buti Hospital Universitario Valle Hebron Barcelona Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck
More informationPreamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 *
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases A new section on Use and Interpretation of
More information